Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 0302

Drug Profile

SHR 0302

Alternative Names: ARQ 252 active ingredient - Jiangsu Hengrui Medicine; SHR-0302

Latest Information Update: 08 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Reistone Biopharma
  • Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antirheumatics; Cyclopentanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Thiadiazoles
  • Mechanism of Action Janus kinase 1 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II/III Ankylosing spondylitis; Atopic dermatitis
  • Phase II Alopecia areata; Crohn's disease; Ulcerative colitis
  • Research Systemic lupus erythematosus

Most Recent Events

  • 04 Feb 2021 Efficacy and adverse events data from a phase II AMBER2 trial in ulcerative colitis released by Reistone Biopharma
  • 04 Feb 2021 Reistone Biopharma completes a phase II AMBER2 trial in Ulcerative colitis in US, China, Poland, Puerto Rico and Ukraine (NCT03675477) (EudraCT2018-003364-31)
  • 04 Feb 2021 Reistone Biopharma plans a phase III trial for ulcerative colitis in 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top